Sugi Predict

Sugi Predict / Compounds / SCHEMBL2844247

SCHEMBL2844247

SCHEMBL2844247

c1ccc(Nc2ccc3ccccc3n2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.59
▸ RAB9A P51151 6/20 0.59
▸ KDM4E B2RXH2 6/20 0.59
▸ SMN1; SMN2 Q16637 5/20 0.59
▸ TP53 P04637 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ HTT P42858 2/20 0.59
▸ TSHR P16473 2/20 0.59
▸ ALOX15 P16050 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ ALOX12 P18054 1/20 0.59
▸ KLF5 Q13887 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ HPGD P15428 2/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ NCF1 P14598 1/20 0.55
▸ ALDH1A1 P00352 4/20 0.54
▸ NFKB1 P19838 2/20 0.54
▸ NFKB2 Q00653 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702119 1.00 NPC1 (0.59) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL10458402 0.86 NCF1 (0.71) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL30760998 0.86 NCF1 (0.71) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL1702196 0.83 NCF1 (0.57) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL28665286 0.82 HTT (0.53) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL1702524 0.81 NCF1 (0.50) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL20913321 0.80 KDM4E (0.48) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL1950236 0.80 KMT2A (0.64) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL4897079 0.80 KMT2A (0.64) NPC1RAB9AKDM4ESMN1; SMN2TP53
SCHEMBL221242 0.79 KMT2A (0.76) NPC1RAB9AKDM4ESMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 — — EP claimed
EP-2440547-B1 New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects ABIVAX (FR) 2022-11-30 — — EP claimed
CN-113717158-A 2- (N- (pyridine-2-yl) amino) quinoline derivative and application thereof 河南省人民医院 2021-11-30 — — CN claimed
EP-2440545-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2019-04-24 — — EP claimed
US-9827237-B2 Compounds useful for treating diseases caused by retroviruses ABIVAX (FR) 2017-11-28 — — US claimed
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-06-02 — — US claimed
EP-3016656-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-05-11 — — EP claimed
US-9108919-B2 Compounds useful for treating cancer ABIVAX (FR) 2015-08-18 — — US claimed
WO-2015001518-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES SPLICOS (FR) 2015-01-08 — — WO claimed
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2014-03-20 — — US claimed
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIETE SPLICOS (FR) 2012-12-27 — — US claimed
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2012-11-08 — — US claimed
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER SOCIETE SPLICOS (FR) 2012-11-01 — — US claimed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 — — WO claimed
EP-2261214-A1 Compounds useful to treat premature aging and in particular progeria Splicos Sas (FR) 2010-12-15 — — EP claimed
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING ABIVAX (FR) 2024-10-17 — — US disclosed
EP-3521283-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2024-02-28 — — EP disclosed
US-6661023-B2 Organic element for electroluminescent devices EASTMAN KODAK COMPANY 2003-12-09 — — US disclosed
US-20030201415-A1 Organic element for electroluminescent devices EASTMAN KODAK COMPANY 2003-10-30 — — US disclosed
EP-1340798-A2 Organic element for electroluminescent devices EASTMAN KODAK COMPANY (US) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR1, CNR1, CBR3 NPC1 45/4885RAB9A 4149/4885KDM4E 3299/4885
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER CBR1, CBR3, NCOR1 NPC1 129/4885RAB9A 4050/4885KDM4E 2650/4885
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING RCOR1, NR3C1, NR5A1 NPC1 80/4885RAB9A 2148/4885KDM4E 3655/4885
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA NR2C2, NCOR2, NR4A2 NPC1 144/4885RAB9A 4270/4885KDM4E 3675/4885
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES RCOR1, CBR1, RCOR3 NPC1 126/4885RAB9A 3396/4885KDM4E 2880/4885
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER NR1H4, NR1H3, NCOR1 NPC1 60/4885RAB9A 1904/4885KDM4E 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.